vs
Bionano Genomics, Inc.（BNGO）与因美纳（ILMN）财务数据对比。点击上方公司名可切换其他公司
因美纳的季度营收约是Bionano Genomics, Inc.的138.9倍（$1.1B vs $8.0M）。因美纳净利率更高（16.8% vs -99.8%，领先116.6%）。因美纳同比增速更快（-1.6% vs -2.6%）。过去两年因美纳的营收复合增速更高（0.8% vs -4.8%）
Bionano Genomics是一家基因组技术企业，开发并销售专有光学基因组测绘技术及相关诊断解决方案，可高精度检测基因组大型结构变异，服务全球学术研究机构、生物制药企业与临床诊断实验室，产品应用于肿瘤、罕见病研究等领域。
因美纳是总部位于美国加利福尼亚州圣迭戈的生物技术企业，成立于1998年4月，专注研发、生产及销售用于分析基因变异与生物功能的集成系统，产品及服务覆盖测序、基因分型、基因表达、蛋白质组学等领域，业务遍及全球超155个国家和地区。
BNGO vs ILMN — 直观对比
营收规模更大
ILMN
是对方的138.9倍
$8.0M
营收增速更快
ILMN
高出1.0%
-2.6%
净利率更高
ILMN
高出116.6%
-99.8%
两年增速更快
ILMN
近两年复合增速
-4.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $8.0M | $1.1B |
| 净利润 | $-7.9M | $186.0M |
| 毛利率 | 42.8% | 65.9% |
| 营业利润率 | -107.4% | 15.8% |
| 净利率 | -99.8% | 16.8% |
| 营收同比 | -2.6% | -1.6% |
| 净利润同比 | 60.6% | 205.7% |
| 每股收益（稀释后） | $-0.12 | $1.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BNGOILMN
| Q4 25 | $8.0M | — | ||
| Q3 25 | $7.4M | — | ||
| Q2 25 | $6.7M | — | ||
| Q1 25 | $6.5M | — | ||
| Q4 24 | $8.2M | $1.1B | ||
| Q3 24 | $6.1M | $1.1B | ||
| Q2 24 | $7.8M | $1.1B | ||
| Q1 24 | $8.8M | $1.1B |
净利润BNGOILMN
| Q4 25 | $-7.9M | — | ||
| Q3 25 | $-8.5M | — | ||
| Q2 25 | $-6.9M | — | ||
| Q1 25 | $-3.1M | — | ||
| Q4 24 | $-20.1M | $186.0M | ||
| Q3 24 | $-44.2M | $705.0M | ||
| Q2 24 | $-16.2M | $-2.0B | ||
| Q1 24 | $-31.4M | $-126.0M |
毛利率BNGOILMN
| Q4 25 | 42.8% | — | ||
| Q3 25 | 45.7% | — | ||
| Q2 25 | 51.6% | — | ||
| Q1 25 | 45.5% | — | ||
| Q4 24 | 41.9% | 65.9% | ||
| Q3 24 | -139.1% | 69.0% | ||
| Q2 24 | 33.3% | 64.8% | ||
| Q1 24 | 32.2% | 62.0% |
营业利润率BNGOILMN
| Q4 25 | -107.4% | — | ||
| Q3 25 | -115.9% | — | ||
| Q2 25 | -115.8% | — | ||
| Q1 25 | -131.1% | — | ||
| Q4 24 | -146.3% | 15.8% | ||
| Q3 24 | -722.9% | 68.6% | ||
| Q2 24 | -219.0% | -147.2% | ||
| Q1 24 | -354.9% | -10.3% |
净利率BNGOILMN
| Q4 25 | -99.8% | — | ||
| Q3 25 | -115.4% | — | ||
| Q2 25 | -101.8% | — | ||
| Q1 25 | -48.0% | — | ||
| Q4 24 | -246.5% | 16.8% | ||
| Q3 24 | -728.6% | 65.3% | ||
| Q2 24 | -208.8% | -178.8% | ||
| Q1 24 | -358.3% | -11.7% |
每股收益（稀释后）BNGOILMN
| Q4 25 | $-0.12 | — | ||
| Q3 25 | $-1.59 | — | ||
| Q2 25 | $-1.99 | — | ||
| Q1 25 | $-1.15 | — | ||
| Q4 24 | $-7.05 | $1.16 | ||
| Q3 24 | $-30.92 | $4.42 | ||
| Q2 24 | $-14.41 | $-12.48 | ||
| Q1 24 | $-35.75 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $93.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $44.4M | $2.4B |
| 总资产 | $73.6M | $6.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BNGOILMN
| Q4 25 | $3.0M | — | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | $3.6M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $9.2M | $93.0M | ||
| Q3 24 | $8.8M | $70.0M | ||
| Q2 24 | $10.4M | $74.0M | ||
| Q1 24 | $15.8M | — |
股东权益BNGOILMN
| Q4 25 | $44.4M | — | ||
| Q3 25 | $49.8M | — | ||
| Q2 25 | $45.4M | — | ||
| Q1 25 | $48.2M | — | ||
| Q4 24 | $35.4M | $2.4B | ||
| Q3 24 | $48.9M | $2.1B | ||
| Q2 24 | $80.3M | $1.4B | ||
| Q1 24 | $82.8M | $5.7B |
总资产BNGOILMN
| Q4 25 | $73.6M | — | ||
| Q3 25 | $79.1M | — | ||
| Q2 25 | $76.0M | — | ||
| Q1 25 | $78.4M | — | ||
| Q4 24 | $76.7M | $6.3B | ||
| Q3 24 | $87.4M | $6.0B | ||
| Q2 24 | $129.4M | $6.1B | ||
| Q1 24 | $158.0M | $10.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.2M | $364.0M |
| 自由现金流经营现金流 - 资本支出 | — | $335.0M |
| 自由现金流率自由现金流/营收 | — | 30.3% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.96× |
| 过去12个月自由现金流最近4个季度 | — | $709.0M |
8季度趋势，按日历期对齐
经营现金流BNGOILMN
| Q4 25 | $-4.2M | — | ||
| Q3 25 | $-5.9M | — | ||
| Q2 25 | $-3.5M | — | ||
| Q1 25 | $-2.8M | — | ||
| Q4 24 | $-6.5M | $364.0M | ||
| Q3 24 | $-13.3M | $316.0M | ||
| Q2 24 | $-21.0M | $80.0M | ||
| Q1 24 | $-28.1M | $77.0M |
自由现金流BNGOILMN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $335.0M | ||
| Q3 24 | — | $284.0M | ||
| Q2 24 | — | $49.0M | ||
| Q1 24 | — | $41.0M |
自由现金流率BNGOILMN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 30.3% | ||
| Q3 24 | — | 26.3% | ||
| Q2 24 | — | 4.4% | ||
| Q1 24 | — | 3.8% |
资本支出强度BNGOILMN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 3.0% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 3.3% |
现金转化率BNGOILMN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.96× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BNGO
暂无分部数据
ILMN
| Sequencing | $1.0B | 91% |
| Microarray | $101.0M | 9% |
| Investee | $7.0M | 1% |
